Anti-RUNX1 / AML1 Antibody - ChIP Grade (RMAB-0251013)
Cat. No.: RMAB-0251013
Category: Primary Antibodies
INQUIRY
100 μL
Customer Size
Rabbit monoclonal to RUNX1 / AML1 - ChIP Grade
Product Features
| Isotype | IgG |
|---|---|
| Clonality | Monoclonal |
| Host Species | Rabbit |
| Clone Number | EPR23309-113 |
| Form | Liquid |
| Purity | Protein A purified |
| Species Reactivity | Human |
| Immunogen | Recombinant fragment. |
| Applications | ChIC/CUT&RUN-seq, Flow Cyt (Intra), WB, ChIP, IP |
| Key Features | Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply; Rabbit monoclonal to RUNX1 / AML1 - ChIP Grade; Suitable for: ChIC/CUT&RUN-seq, Flow Cyt (Intra), WB, ChIP, IP; Reacts with: Human |
Target Information
| Target Symbol | RUNX1 |
|---|---|
| Target Name | Runt-related transcription factor 1 |
| UniProt ID | Q01196 |
| Cellular Localization | Nucleus. |
| Function | CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits MYST4-dependent transcriptional activation. |
| Involvement in Disease | A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8; 21)(q22; q22) with RUNX1T1.A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3; 21)(q26; q22) with EAP or MECOM.A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3; 21)(q26; q22) with EAP or MECOM.A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12; 21)(p13; q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13; q22) that forms a MACROD1-RUNX1 fusion protein.Defects in RUNX1 are the cause of familial platelet disorder with associated myeloid malignancy (FPDMM). FPDMM is an autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16; 21)(q24; q22) that forms a RUNX1-CBFA2T3 fusion protein.A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21; q22) with USP16. |
| Post-translational Modifications | Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with MYST3. Methylated. |
| Domain | A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes. |
| Sequence Similarities | Contains 1 Runt domain. |
Storage & Shipping
| Storage Buffer | pH: 7.2; Preservative: 0.01% Sodium azide; Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA |
|---|---|
| Storage & Shipping | Shipped at 4°C. Store at 4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. |
For research use only. Not for clinical use.
